Infectious alliance between diagnostic behemoths Siemens and Illumina
Munich/San Diego – New challenges breed new alliances. Siemens Healthcare, the health-tech subsidiary of the German technology giant, and Next-Generation sequencing world market leader Illumina, want to make rules for using next-generation sequencing in rapid disease identification. As a first concrete step, the partners want to tweak Siemens' molecular HIV tests so that they are compatible with Illumina's new NGS desktop sequencer MiSeq. If this works, the two companies want to present more sequencing-based infectious disease assays for the clinical diagnostics market."Next-generation sequencing is a transformational technology that we believe will significantly impact clinical diagnostics over the next five years," said Michael Reitermann, CEO, Siemens Healthcare Diagnostics. The new partnership aims to set first standards for this new business segment, Reitermann said. For 10 years now Siemens has a DNA sequencing-based assay on offer which can test for resistance in HIV. The Trugene HIV-1 Genotyping Assay was the first such kit to for HIV to be cleared by the FDA.